President and Chief Executive Officer at Adverum Biotechnologies, Inc. - Redwood City, CA, US
Director, Translational Medicine Leader, Clinical Development/Translational Medicine
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with neovascular or wet age-related macular degeneration.